AngioDynamics (ANGO) Misses Q1 EPS by 4c, Reaffirms FY18 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics Reports Fiscal 2018 First Quarter Results
September 28, 2017 6:00 AM EDTQ1 net sales of $85.4 million, down 3% year-over-year       Q1 GAAP earnings per share of $0.00; adjusted EPS of $0.12Q1 operating cash generation of $3.0 million; free cash flow generation of $2.5 millionCompany reaffirms fiscal 2018 guidance
ALBANY, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported first quarter financial results for the 2018 fiscal year ended August 31, 2017.
The first quarter of fiscal 2018 reflects early results of our commitment to improving our core operational efficiency and... More
